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Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin
lymphoma but heterogeneity in response duration is observed, with some
patients achieving cure and others showing refractory disease or relapse.
Using a transcriptome-powered targeted proteomics screen, we discovered
a gene regulatory circuit involving the nuclear factor CYCLON which
characterizes aggressive disease and resistance to the anti-CD20 monoclonal
antibody, Rituximab, in high-risk B-cell lymphoma. CYCLON knockdown
was found to inhibit the aggressivity of MYC-overexpressing tumours in mice
and to modulate gene expression programs of biological relevance to
lymphoma. Furthermore, CYCLON knockdown increased the sensitivity of
human lymphoma B cells to Rituximab in vitro and in vivo. Strikingly,
this effect could be mimicked by in vitro treatment of lymphoma B cells with
a small molecule inhibitor for BET bromodomain proteins (JQ1). In summary,
this work has identified CYCLON as a new MYC cooperating factor that
autonomously drives aggressive tumour growth and Rituximab resistance in
lymphoma. This resistance mechanism is amenable to next-generation
epigenetic therapy by BET bromodomain inhibition, thereby providing a new
combination therapy rationale for high-risk lymphoma.
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INTRODUCTION
B‐cell non‐Hodgkin lymphoma (B‐NHL) is a clinically heteroge-
neous disease that is currently classiﬁed into multiple disease
subtypes deﬁned by discrete clinical, morphological, immuno-
logical and genetic features (Swerdlow et al, 2008). Molecular
proﬁling studies in diffuse large B‐cell lymphoma (DLBCL), the
most common form of B‐NHL, have revealed the existence of
three molecular subtypes, the germinal centre B‐cell‐like (GCB‐
DLBCL), the activated B‐cell‐like (ABC‐DLBCL) and primary
mediastinal large B‐cell lymphoma (Alizadeh et al, 2000;
Pasqualucci, 2013). ABC‐DLBCL consistently shows inferior
survival compared to the GCB‐DLBCL particularly under the
current, standard‐of‐care, immuno‐chemotherapy regimen,
R‐CHOP [Rituximab, Cyclophosphamide, Doxorubicin Hydro-
chloride, Vincristine Sulphate (Oncovin), Prednisone] (Lenz
et al, 2008). However, treatment failure is also observed in
GCB‐DLBCL (20% within the ﬁrst 2 years, based on progression
free survival) (Lenz et al, 2008). Although MYC gene alterations
are implicated in this setting and are associated with poor
outcome (Barrans et al, 2010; Cuccuini et al, 2012; Johnson
et al, 2009; Savage et al, 2009; Visco et al, 2013), the speciﬁc
effectors of MYC dependency in DLBCL are not well character-
ized (Aukema et al, 2011). Aggressive lymphoma with features
intermediate between DLBCL and Burkitt lymphoma (BL) are
also described (Swerdlow et al, 2008). In a signiﬁcant subset of
cases, these are characterized by concurrent MYC and BCL2 or
BCL6 gene translocations (Aukema et al, 2011; Lindsley &
LaCasce, 2012). Lymphoma presenting this cytogenetic proﬁle
are commonly referred to as ‘double hit’ lymphoma. Despite
their poor prognosis, evidence‐based, risk‐adapted treatment
strategies and clinical, pathologic and genetic factors that
predict response to therapy are lacking in these cases (Aukema
et al, 2011; Lindsley & LaCasce, 2012).
We have postulated that a universal consequence of genetic
and epigenetic perturbations in cancer cells, including lympho-
ma, is the illegitimate activation of cell type or differentiation
stage‐speciﬁc genes and proteins (Rousseaux & Khochbin, 2009;
Wang et al, 2011), a process that we refer to as ‘off‐context’
gene activation. We further propose that this ‘off‐context’ gene
expression provokes a cancer cell ‘identity crisis’ that permits
evasion from normal cellular controls, ultimately leading to
disease progression and treatment resistance (Rousseaux &
Khochbin, 2009; Wang et al, 2011). This concept is best
exempliﬁed by the case of aberrant expression of testis speciﬁc/
germ cell factors in somatic cancer cells (Rousseaux et al, 2013).
Important in this respect is the fact that a signiﬁcant proportion
of testis speciﬁc genes encode potent epigenetic writers or
readers that control reprogramming of the meiotic and post‐
meiotic haploid genome from a ‘somatic type’ organization to a
gamete speciﬁc organization, involving almost genome wide
replacement of histones and successive assembly of transition
proteins and protamines (Rousseaux & Khochbin, 2009).
Aberrant expression of testis speciﬁc factors, including epige-
netic regulators, is increasingly described in diverse cancer types
(Wang et al, 2011). This appears to drive abnormal epigenome
reprogramming leading to malignant transformation and the
emergence of cancer cell clones. As an example, expression of
the male germ cell factor, DNMT3L, a catalytically inactive
member of DNA methyl transferases, has been described in a
variety of cancers. Through its ability to increase the activity of
the de novomethyl transferases, it could contribute to CpG island
methylation and pathological gene silencing (Gokul et al, 2009).
Likewise, expression of NUT (nuclear protein in testis), encoded
by a testis speciﬁc gene, is abnormally activated through fusion
with the ubiquitously expressed BET bromodomain protein‐
encoding gene, BRD4, in an aggressive subset of carcinoma
known as NUT‐Midline Carcinoma (French, 2012). The resultant
BRD4‐NUT fusion gene encodes a fusion protein that behaves
as a histone superacetylator, resulting in chromatin hyper-
acetylation that completely alters the epigenetic landscape of
the affected cells (Reynoird et al, 2010). Finally, gene expression
proﬁling in malignant brain tumours derived by inactivation of
the l(3)mbt tumour suppressor in Drosophila, has revealed
predominant expression of germline speciﬁc transcripts some
of which were found to be essential for tumour growth (Janic
et al, 2010).
In this setting, we have devised a novel, transcriptome‐driven,
proteomics approach to identify candidate, ‘off‐context’ factors
likely to be involved in tumour progression and immuno‐
chemotherapy resistance in lymphoma (Fig 1A). Speciﬁcally,
we geared our screening procedures to identify abnormally
expressed, positively‐charged, nuclear factors as these were
likely to bind nucleic acids and to directly or indirectly engage
aberrant and potentially druggable gene regulatory pathways in
lymphoma. By using this strategy, we have discovered a novel
Rituximab resistance mechanism that depends on MYC‐driven
overexpression of the nuclear, male germ cell factor, CYCLON.
Remarkably, this resistance can be relieved by treatment with
small molecule inhibitors of BET bromodomain‐dependent
chromatin signalling. Furthermore, CYCLON was identiﬁed to
be an autonomous tumour growth driver that cooperates with
MYC to drive aggressive lymphoma growth in vivo thus further
rationalizing the value of therapeutically targeting this factor
in lymphoid malignancies.
RESULTS
Proteomics‐based identiﬁcation of nuclear factors that show
unscheduled activation in lymphoma
To identify candidate nuclear factors associated with aggressive
disease and treatment resistance in lymphoma, we ﬁrst derived
an inventory of positively charged nuclear proteins in the DLBCL
line, B593. This lymphoma cell line was chosen as it harbours
both BCL2 and MYC gene translocations (Le Baccon et al,
2001) and therefore represents a good model system for the
investigation of disease mechanisms in aggressive ‘double hit’
DLBCL. The inventory of positively charged nuclear proteins, in
B593 DLBCL cells, was achieved by extracting the acid soluble
fraction (Supporting Information Fig S1A) of nuclear proteins
(NAS fraction) followed by mass spectrometry (MS) sequencing
of the isolated proteins (Fig 1A and Supporting Information
Fig S1A, B). Due to enrichment of the acid‐soluble proteome in
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nucleic acid binding factors, we reasoned that we should also
ﬁnd, within this particular proteome, deregulated factors
capable of impacting gene/protein expression and contributing
to malignant transformation. Indeed, our previous work on acid
soluble fractions from male germ cells (Govin et al, 2006) had
shown that this fraction is highly enriched in nucleic acid‐
binding factors, since the majority of identiﬁed proteins were
known or potential DNA and RNA binding factors. This also
showed that charge interaction between positively charged
proteins and negatively charged nucleic acids is a prevalent
determinant of protein–nucleic acid interactions in nature. In
keeping with this, MS sequencing of the NAS protein fraction in
our model DLBCL cell line, identiﬁed a total of 236 proteins
of which a majority represented nuclear DNA/RNA binding
proteins (Supporting Information Fig S1B and Table S1). The
next step was to identify those factors that showed clear
evidence of ‘off‐context’ expression in the reference DLBCL
lymphoma cell line. For this, normal tissue and cell type speciﬁc
gene expression data were retrieved from the BioGPS database
(which contains expression data for 79 normal tissues/cell
types) for each of the 236 NAS proteins (Supporting Information
Fig S1C). ‘Off‐context’ factors were deﬁned by a level of
expression in at least one non‐lymphoid normal tissue that was
greater than 10‐fold the median expression value across all of
79 normal tissues/cell types. By using this stringent cut‐off,
6 factors expressed predominantly in brain (MECP2, STMN2),
lung (H2AFY, NUMA1), and testis (CYCLON, LYAR), were
identiﬁed as showing abnormally high expression in the index
DLBCL cell line (Table 1 and Fig 1B). It is noteworthy, that for
two of these factors (CYCLON and H2AFY) spectral counts in the
NAS proteome of the reference DLBCL cell line were close to
those observed for core histones (Supporting Information
Fig S1D), reﬂecting their remarkably high abundance in the
B593 NAS fraction. Subsequently, interrogation of publically
available data sets (Basso et al, 2005) for 5 of these 6 genes
(probes were unavailable for LYAR) conﬁrmed low or absent
expression in normal B‐cell subsets and high expression in either
indolent (NUMA1, MECP2, STMN2) or aggressive lymphoid
malignancies (H2AFY, CYCLON), including BL, DLBCL and
primary effusion lymphoma (PEL), respectively (Fig 1C). Taken
together, these ﬁndings validate the clinical relevance of our
biomarker discovery approach and identify candidate nuclear
factors of potential relevance to the pathogenesis of lymphoid
malignancies.
CYCLON overexpression is linked to adverse clinical outcome in
immunochemotherapy‐treated DLBCL
CYCLON is a novel, cytokine‐inducible, nuclear phosphoprotein
(Hoshino & Fujii, 2007) that bears a coiled coil domain, also
sharedwithmany transcription factors, whereasH2AFY encodes
a histone variant that has been shown to inﬂuence prognosis in
malignant melanoma and lung cancer (Kapoor et al, 2010; Sporn
et al, 2009). Given their potential role in driving aberrant gene
expression in cancer, H2AFY and CYCLON were selected for
further analysis of their clinical relevance in lymphoma. Using
publically available, clinically annotated transcriptomic data in
DLBCL, we tested the association between overexpression of
H2AFY and CYCLON and survival (Lenz et al, 2008). We
identiﬁed high‐level expression of CYCLON mRNA, but not of
H2AFY, to be signiﬁcantly correlated to poor survival in DLBCL
(Fig 2A and Supporting Information Fig S2A). Signiﬁcantly, high
level CYCLON expression was associated with inferior outcome
Figure 1. Proteomics‐based discovery strategy for identiﬁcation of abnormally expressed nuclear factors in lymphoma.
A. Schematic representation of the overall experimental strategy, as indicated. NAS: nuclear acid-soluble, MS: mass spectrometry.
B. Heat-map representation of the gene expression levels for 6 candidate ‘off-context’ genes in normal lymphoid and non-lymphoid tissues; PB: peripheral blood
[data from BioGPS (Su et al, 2004)].
C. Heat-map representation of gene expression profiles for 5 ‘off-context’ genes, as indicated; NHL: non-Hodgkin lymphoma, B-CLL: B-cell chronic lymphocytic
leukemia, FL: follicular lymphoma, HCL: hairy cell leukemia, MCL: mantle cell lymphoma, BL: Burkitt lymphoma, DLBCL: diffuse large B-cell lymphoma, PEL:
primary effusion lymphoma [data from GEO GSE2350 (Basso et al, 2005)].
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in R‐CHOP but not CHOP‐treated DLBCL patients (Fig 2B and
Supporting Information Fig S2B). Further survival analysis,
according to DLBCL molecular subtype, showed a marked
tendency towards poor survival in R‐CHOP‐treated DLBCL of the
GCB but not the ABC subtype (Fig 2C). High CYCLON expression
was not associated to poor survival in CHOP‐treated patients of
either molecular subtype (Supporting Information Fig S2C).
Taken together this indicated that CYCLON could be a novel
Rituximab response factor, at least in DLBCL of the GCB subtype.
RT‐qPCR analysis in a panel of normal tissues and lymphoma
lines subsequently revealed high CYCLON expression in testis
and in DLBCL and BL, as expected from our initial analysis, and
low expression elsewhere including normal lymph node and
peripheral blood B cells (Fig 2D). This was conﬁrmed by gene
expression analysis in additional publically available tran-
scriptomic data sets (Basso et al, 2005) (Fig 2E), which further
revealed high CYCLON expression in both the GCB and ABC
subtypes of DLBCL (Lenz et al, 2008) (Fig 2F). Protein
abundance and mRNA levels in B‐cell lymphoma lines showed
good correlation, indicating that CYCLON mRNA expression
reﬂects protein expression (Fig 2D, upper panel).
CYCLON is a MYC target that constrains MYC‐dependent
tumour growth in vivo
High CYCLON expression was observed in BL, an MYC‐
dependent lymphoma (Mertz et al, 2011), and in aggressive
DLBCL (of both the GCB and ABC subtypes), but not in other
lymphoid malignancies. We thus considered whether CYCLON
expression might be dependent on MYC. In keeping with this,
MYC knockdown in Raji BL cells resulted in down‐regulation of
CYCLON at both themRNA and protein levels (Fig 3A). This was
in agreement with results in a gene expression data set from a
MYC‐inducible B‐cell line (Schlosser et al, 2005), where MYC
activation led to marked up‐regulation of the CYCLON gene
(Fig 3B). In addition, high CYCLON expression was signiﬁcantly
associated with highMYC expression in DLBCL of both the GCB
and ABC subtypes, suggestive of co‐selection of these two events
in the pathogenesis of DLBCL (Fig 3C) (Lenz, p < 0.0001,
Hummel, p ¼ 0.0003). Taken together, these data raised the
possibility that CYCLON is a key downstream effector of
oncogenic MYC signalling in lymphoma. In support of this,
SCID mice engrafted with CYCLON‐knockdown (transduced by
shCYCLON) Raji BL cells (Supporting Information Fig S3A)
showed signiﬁcantly reduced tumour size and increased survival
(Fig 3D, E), compared to mice engrafted with control Raji cells
(transduced by non‐targeting shRNA). CYCLON knockdown
did not alter MYC levels in Raji or other lymphoma lines tested
(Supporting Information Fig S3). This indicates that CYCLON
overexpression is an autonomous tumour growth driver that
cooperates with MYC to drive lymphoma progression.
CYCLON is a novel transcriptional regulator that controls gene
expression programs of biological relevance to lymphoma
pathogenesis
To gain insight into the possible function of CYCLON in the
pathogenesis and treatment resistance of B‐cell malignancies,
we performed gene expression proﬁling in CYCLON‐knockdown
or control Raji BL cells. This analysis revealed a total of 1204
differentially expressed genes (unpaired t‐test with Benjamini–
Hochberg correction; corrected p value <0.05 and fold change
1.2), including 842 up‐regulated and 362 down‐regulated
genes, in the knockdown compared to the control cells
(Supporting Information Fig S4 and Table S2), indicating that
CYCLON has both activating and repressive effects but
predominantly functions in gene repression. We then performed
unbiased gene set enrichment analysis (GSEA) to identify gene
signatures (i.e. pre‐deﬁned lists of genes that are associated to a
speciﬁc biological function) regulated by CYCLON. This analysis
revealed signiﬁcant down‐regulation by CYCLON knockdown of
a proliferation gene expression signature that includes cancer
testis antigens (e.g.MAGEA1,MAGEA3,MAGEA6, GAGE1), and
that characterizes an aggressive subtype of multiple myeloma
Table 1. ‘Off‐context’ candidates identiﬁed in the nuclear acid soluble fraction from the DLBCL line, B593
Gene
name
Protein
description
Cellular
component
Biological
process
Predominant
normal tissue
expression
Spectral
counts
Position in B596
NAS fraction (sorted
by spectral counts)
CCDC86 Cytokine-induced protein
with coiled-coil domain
Nucleus Unknown Testis 106 22/236
H2AFY Core histone
macro-H2A.1
Nucleus Chromatine
Structure
Lung 42 44/236
MECP2 Methyl-CpG-binding
protein 2
Nucleus Chromatine
Structure
Brain 16 85/236
NUMA1 Nuclear mitotic apparatus
protein 1
Nucleus Cell cycle Lung 14 90/236
LYAR Cell growth-regulating
nucleolar protein
Nucleus Cell cycle Testis 10 106/236
STMN2 Stathmin-2 Cytoskeleton Microtubule
polymerization
Brain 1 219/236
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(Zhan et al, 2006) (Fig 4A and Supporting Information Table S3).
GSEA also revealed up‐regulation of a previously‐deﬁned, CD40‐
regulated, mature B‐cell‐speciﬁc gene expression signature
(Basso et al, 2004), in the CYCLON‐knockdown compared to
control lymphoma Raji BL cells (Fig 4B and Supporting
Information Table S4). This is of interest since the germinal
centre B‐cell is the presumed cell of origin for both DLBCL and
BL. The CD40‐regulated ‘mature B‐cell signature’ comprises
genes of known importance in DLBCL/BL pathogenesis
including NFKB2,MEF2C (Wilker et al, 2008) and TNFAIP genes
(Compagno et al, 2009; Kato et al, 2009; Lohr et al, 2012). A
number of these signature genes were among the top 50
CYCLON up or down‐regulated genes (Fig 4C). Collectively,
these data identify CYCLON as a transcriptional regulator whose
Figure 2. CYCLON overexpression is a feature of aggressive NHL and correlates to adverse clinical outcome in DLBCL.
A. Kaplan–Meier cumulative survival curves in DLBCL patients from GEO GSE10846 (Lenz et al, 2008) according to CYCLON expression level (high: above 3rd
quartile and low: below 1st quartile, respectively), p values from log-rank test.
B. Survival curves according to CYCLON expression levels in DLBCL patients treated by Rituximab-CHOP (left panel, R-CHOP) or CHOP alone (right panel),
p-values from log-rank test.
C. Survival curves according to CYCLON expression levels in ABC or GCB DLBCL patients treated by Rituximab-CHOP, p-values from log-rank test.
D. RT-qPCR and western blot (upper panel) analysis of CYCLON expression in normal lymphoid and non-lymphoid tissues, and in lymphoma lines, as indicated:
PB B: peripheral blood B cells, LN: lymph node, BM: bone marrow, n ¼ 3.
E,F. Affymetrix-derived CYCLON gene expression values for individual patients from GEO GSE2350 (Basso et al, 2005), p-value from Wilcoxon test (E) and
GEO GSE10846 (Lenz et al, 2008) (F).
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‘off‐context’ expression drives gene expression programs of
biological relevance to lymphoma pathogenesis.
CYCLON modulates Rituximab sensitivity in vitro and in vivo
High CYCLON expression was signiﬁcantly associated to high
MYC expression and was correlated with inferior clinical
outcome in R‐CHOP but not CHOP‐treated DLBCL patients,
particularly of the GCB‐subtype. This suggested a role for
CYCLON as a key MYC effector in modulating treatment
response, in particular to Rituximab, at least in BL and DLBCL of
the GCB subtype. To investigate this in more detail we ﬁrst
looked at CYCLON and MYC expression in a panel of BL (Raji,
BL41, BL136) and DLBCL cell lines of both the GCB (B593,
SUDHL4, HT) and ABC subtypes (OCI‐LY3, OCI‐LY10) (Fig 5A).
Coincident CYCLON and MYC deregulation was detected in 5 of
8 lymphoma cell lines tested (BL cell lines Raji, BL41 and BL136
and in the GCB‐type DLBCL, B593 and SUDHL4) (Fig 5A). Three
of eight lymphoma cell lines (but no BL line) showed moderate
(HT) to high CYCLON overexpression in the absence of marked
MYC overexpression, thus suggesting the existence of alternate
routes to CYCLON overexpression in these cells. We next
tested sensitivity to Rituximab‐mediated, complement‐depen-
dent cytotoxicity (CDC, Fig 5B) and direct killing (Fig 5C) in a
selection of these cell lines. In the conditions used for these
assays, lymphoma cells that showed coincident CYCLON and
MYC deregulation (Raji, B593, SUDHL4 cells, respectively) were
sensitive to both Rituximab‐induced, complement‐mediated
cytotoxicity and direct killing while the remaining cell lines were
resistant (Fig 5B, C). The observed effects were not related to
differences in the cell surface expression of the Rituximab target
receptor, CD20, which was broadly similar across all cell lines
(Fig 5D). In order to further explore the role of CYCLON in
Rituximab response in lymphoma, short hairpin RNA was used
to deplete CYCLON in Raji, B593 and SUDHL4 as well as in
OCI‐Ly3 cells. Consistent with a role for CYCLON in Rituximab
response in lymphoma, CYCLON depletion markedly increased
the sensitivity of B593, SUDHL4 (DLBCL cell lines) and Raji (BL)
lymphoma cells to Rituximab‐dependent killing, particularly
complement‐mediated cytotoxicity (Fig 5E, F and Supporting
Information Fig S5A, B). In contrast, CYCLON depletion was not
sufﬁcient to relieve Rituximab resistance in the OCI‐Ly3 cell line.
This suggests a requirement for even lower CYCLON thresholds
to restore Rituximab response and/or the existence of alternative
resistance routes, in these cells. CYCLON depletion was not
associated to increased antibody‐dependent, cell‐mediated
cytotoxicity, at least in Raji cells (ADCC, Supporting Information
Fig S5C). CYCLON depletion did not increase the apoptotic
responses in any of the cell lines, following treatment by
Figure 3. CYCLON is a MYC target involved in lymphoma progression in vivo.
A. Analysis by RT-qPCR and western blot (upper and lower panels, respectively) of CYCLON expression in control and MYC-knockdown Raji lymphoma B cells,
n ¼ 3.
B. CYCLON gene expression values in the MYC-inducible cell line, P493 (Schlosser et al, 2005).
C. Affymetrix-derived MYC gene expression values for DLBCL in GEO GSE10846 (Lenz et al, 2008) and GEO GSE4475 (Hummel et al, 2006); high CYCLON
expression: above 3rd quartile; low CYCLON expression: below 1st quartile, p-values from Student t test.
D. Kaplan–Meier cumulative survival curves for xenotransplanted mice bearing tumours derived from Raji shCtrl and Raji shCYCLON cell lines, p-value from log-
rank test.
E. Tumour weight (28 days post-injection) for xenotransplanted mice bearing tumours derived from Raji shCtrl and Raji shCYCLON cell lines, n ¼ 11 for each
group, p-value from Wilcoxon test (left) and bioluminescence imaging for 4 representative mice (right).
Research Articlewww.embomolmed.org
Anouk Emadali et al.
EMBO Mol Med (2013) 5, 1180–1195  2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1185
Figure 4. CYCLON regulates gene signatures associated with B‐cell differentiation and proliferation.
A,B. Gene Set Enrichment Analysis (GSEA) enrichment plots obtained from gene expression data from CYCLON knockdown Raji cells (shCYCLON, n ¼ 4) compared
to control Raji cells (shCTRL, n ¼ 4) with associated heat-maps (left). GSEA enrichment plots show down-regulation of aggressive multiple myeloma
signature (A) and up-regulation of a CD40-dependent B-cell signature (B) in CYCLON knock-down compared to control Raji lymphoma B cells. Genes are
ordered on the x axis by their differential expression score (each vertical line representing a gene).
C. Top 50 genes up-regulated (red) or down-regulated (blue) upon CYCLON knockdown (shCYCLON) in Raji lymphoma B cells compared to control (shCtrl). Gene
sets are from MSIGDB collection. See the Materials and Methods section and supplementary material for detailed data analysis.
D. Heat-map representation of co-regulated genes upon CYCLON knockdown and JQ1 treatment in Raji cells (data from GSE29449, Mertz et al, 2011).
E. Venn diagram showing the overlap between differentially expressed genes upon CYCLON knockdown and JQ1 treatment in Raji cells (data from GSE29449,
Mertz et al, 2011) and list of commonly down- and up-regulated genes. Black and green arrows: genes cited in text. Green arrows refer to genes commonly
regulated by CYCLON and JQ1 within the CD40 signature.
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Figure 5. CYCLON‐mediated resistance to Rituximab in BL and MYC‐overexpressing DLBCL.
A. Western Blot analysis of CYCLON, MYC and histone H3 (as loading control) expression in levels in a panel of BL and DLBCL cell lines.
B,C. Evaluation of basal Rituximab sensitivity using CDC (complement dependent cytoxicity) in the presence (þcplt) or absence of human complement (cplt)
(B) and Rituximab-induced direct killing (C) assays as described in the Materials and Methods section, n ¼ 6.
D. Flow cytometry analysis of CD20 expression in a panel of BL and DLBCL cell lines, n ¼ 3.
E,F. Rituximab (E: CDC; F: direct killing) sensitivity of CYCLON knockdown (shCYCLON) Raji (BL), B593, SUDHL4 and OCI-Ly3 (DLBCL) lymphoma B cells compared
to controls (shCtrl); p values from a Wilcoxon test, n ¼ 8 for each cell line, ns: non-significant.
G. Left panel: bioluminescence imaging of Rituximab response (200 mg/day of Rituximab) in SCID mice xenotransplanted with shCtrl or CYCLON knockdown
Raji lymphoma as indicated compared to control-treated mice (IgG for 14 days). Right panel: Relative tumour growth at days 0, 7 and 14, as indicated;
p-value from a Wilcoxon test, n ¼ 6 for each group.
[Correction added after publication on 4 July 2013: The figure title “CYCLON-mediated increase in Rituximab sensitivity in BL and MYC-dependent DLBCL” was
corrected to “CYCLON-mediated resistance to Rituximab in BL and MYC-overexpressing DLBCL”]
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etoposide (Supporting Information Fig S5D) or CD95/FAS
receptor engagement (Supporting Information Fig S5E), which
CYCLON is known to regulate, at least in T cells (Saint Fleur
et al, 2009). This indicated that CYCLON overexpression directly
drives tumour cell intrinsic mechanisms that speciﬁcally impact
on Rituximab response. To test the relevance of this mechanism
in vivo, we subcutaneously injected SCID mice with Raji cells
expressing either CYCLON targeting or non‐targeting shRNA.
Once tumours were established, mice were treated with daily
injections of either Rituximab or control antibody for a period
of 14 days. Rituximab monotherapy signiﬁcantly reduced the
tumour burden in mice engrafted with shCYCLON compared to
control lymphoma cells (Fig 5G). Together, these data identify
CYCLON as a novel Rituximab responsemodulator of interest for
therapeutic targeting in lymphoma.
BET bromodomain inhibition increases Rituximab sensitivity in
CYCLON and MYC overexpressing lymphoma cells
Small molecule inhibitors of BET bromodomain proteins (JQ1,
iBET) have recently been shown to attenuate MYC‐driven
oncogenic signalling in lymphoma and myeloma (Delmore
et al, 2011; Mertz et al, 2011; Zuber et al, 2011). We thus tested
whether one such inhibitor, JQ1, could relieve CYCLON
overexpression and associated suboptimal Rituximab responses
in lymphoma. We ﬁrst performed a dose‐response experiment to
test the effects of JQ1 on MYC levels in our panel of lymphoma
cell lines. In keeping with previous reports (Mertz et al, 2011),
JQ1 treatment induced pronounced, dose‐dependent MYC
suppression in MYC‐overexpressing lymphoma cells (Raji,
B593, SUDHL4) while suppressive effects were more subtle in
the lymphoma cell lines with lower starting levels of MYC (HT,
OCI‐Ly3 and Ly10) (Fig 6A). We next monitored the effects of
JQ1 on CYCLON expression in the same cells. Based on our
previous results showing that CYCLON can be regulated byMYC
(Fig 3A–C), we predicted that JQ1 would override CYCLON
overexpression in lymphoma cells that showed concomitant
MYC deregulation. In keeping with this, CYCLON suppression,
consistently proceeding MYC down‐regulation, was observed in
the Raji, B593 and SUDHL4 cells but not in the HT, OCI‐Ly3 or
OCI‐Ly10 cells, which show comparatively low starting levels of
MYC (Fig 6A), thus suggesting alternative, BET bromodomain
inhibitor‐insensitive routes to CYCLON deregulation in these
cells. MYC and CYCLON suppression was reversible and
occurred in sequence, as shown by JQ1 washout experiments
in the sensitive lymphoma cells (Raji, B593 and SUDHL4)
(Fig 6B). In these lymphoma lines, it thus seems that JQ1
treatment regulates CYCLON indirectly throughMYC rather than
through BRD4 – or indeed through BRD2 and 3 which JQ1 can
also inhibits (Filippakopoulos et al, 2010). The next step was to
explore the effects of JQ1 on Rituximab response in vitro. For
this, the same 6 lymphoma B‐cell lines, were pre‐treated for 24 h
with 1 mM JQ1 and then challenged with Rituximab. JQ1 pre‐
treatment alone, under these conditions, did not induce cell
death in any of the cell lines tested (Supporting Information Fig
S7A) nor did it signiﬁcantly alter responses to genotoxic agents
such as etoposide (Supporting Information Fig S7B). Strikingly,
JQ1 pre‐treatment followed by Rituximab challenge led to
signiﬁcant and uniform increases in Rituximab‐mediated killing
of lymphoma cells presenting JQ1‐sensitive MYC and CYCLON
deregulation (Raji, B593 and SUDHL4), but not in lymphoma
cells that showed JQ1‐refractory CYCLON overexpression
(HT, OCI‐Ly3 and Ly10) (Fig 6C, D). Rituximab responses in
JQ1‐sensitized lymphoma cells were dose‐dependent up to 1 mm
JQ1 (Fig 5E). Taken together, these data identify a new BET
bromodomain inhibitor‐sensitive Rituximab response pathway
that is controlled by a MYC and CYCLON‐dependent gene
regulatory circuit in lymphoma.
Convergent biological pathways regulated by CYCLON and BET
bromodomain inhibition in lymphoma B cells
In view of the fact that CYCLON acts as an independent tumour
growth driver in MYC‐driven lymphoma, and that MYC and
CYCLON overexpression controls a JQ1‐sensitive Rituximab
resistance pathway, we next wished to investigate the possible
links between CYCLON activity and BET bromodomain
inhibition. For this we compared the gene expression proﬁles
of CYCLON knockdown Raji lymphoma B cells with publically
available gene expression data for JQ1‐treated, Raji lymphoma
B cells (Mertz et al, 2011). This analysis identiﬁed a discrete set
of 85 genes that are commonly regulated by JQ1 treatment and
CYCLON knockdown (15 and 70 genes, respectively, down‐ and
up‐regulated following a JQ1 treatment or shCYCLON) (Fig 4D),
in addition to numerous genes that are independently regulated
under either condition. The core set of commonly down‐
regulated genes included ZBTB2, which encodes a negative
regulator of p53 signalling (Jeon et al, 2009) and POU2F2,
which encodes a homeobox transcription factor involved in the
germinal centre reaction, in response to viral infection
(Karnowski et al, 2012) and that has recently been shown to
be mutated in DLBCL (Zhang et al, 2013) (Fig 4D, E). The core
set of commonly up‐regulated genes included a number that
encode factors involved in pathways of direct relevance to
normal and pathological B‐cell signalling (IL6st, JAK1 and
PIK3R1, for example) (Love et al, 2012; Ngo et al, 2011) as
well as JNK1 which has been implicated in the regulation of
complement dependent cell death (Gancz et al, 2009). Closer
inspection of GSEA signatures across both conditions revealed,
as expected, predominant down‐regulation of MYC signatures/
target genes, including CYCLON itself, in JQ1‐treated but not
CYCLON knockdown lymphoma B cells. Interestingly, co‐
regulation by JQ1 and CYCLON of a subset of genes that
comprise the previously identiﬁed CYCLON‐regulated CD40
signature was also seen. This gene list included the CD40 gene
itself as well as genes encoding signalling factors such as the
NFKB inhibitor, NFKBIA and STAT1 (Fig 4B).
DISCUSSION
Combination immunochemotherapy using anti‐CD20 antibodies
and cytotoxic drugs has led to marked improvements in
treatment response and overall survival in B‐NHL. However,
treatment resistance and relapse remain problematic. This is
spurring the development of alternative treatment strategies,
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including novel therapeutic antibodies, and targeted therapy
strategies aimed at curtailing oncogene dependency pathways in
lymphoid neoplasia (Friedberg, 2011). A major confounding
factor in these efforts, however, is the lack of knowledge on the
cellular and molecular mechanisms that contribute to treatment
resistance. In particular, the nature of signalling pathways that
directly or indirectly control biological and clinical responses
to anti‐CD20 therapy are not well elucidated (Cheson &
Leonard, 2008).
Here, by performing a concept‐driven targeted proteomics
and functional analyses, based on the ectopic activation of
tissue‐speciﬁc genes in cancer, we have identiﬁed a Rituximab
Figure 6. BET bromodomain inhibition overrides CYCLON‐mediated Rituximab resistance.
A. Western Blot analysis of CYCLON,MYC and H3 expression (as loading control) in lymphoma B cells treated for 24 hwith control DMSO (0) or increasing doses
of JQ1 as mentioned, n ¼ 3.
B. Western Blot analysis of CYCLON, MYC and H3 expression (as loading control) in lymphoma B cells treated with control DMSO (0) or 500 nM JQ1 for the
indicated times after treatment and wash-out, n ¼ 3.
C,D. Rituximab (CDC, C; direct killing, D) sensitivity assays of lymphoma B cells after 24 h treatment with control DMSO (JQ1-) or 1 m JQ1 pre-treatment
performed as described in Fig 4E, F; p-values from a Wilcoxon test, n ¼ 4 for each cell line, ns: non-significant.
E. Evaluation of Rituximab sensitivity (CDC) of Raji cells pre-treated for 24 h with control DMSO (0) or increasing doses of JQ1 as mentioned, n ¼ 3 for each cell
line.
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resistance mechanism that operates in aggressive B‐cell
lymphoma and that is mediated by MYC‐driven overexpression
of the nuclear factor, CYCLON. Remarkably, this resistance
mechanism could be alleviated by next generation epigenetic
therapy, using the BET bromodomain small molecule inhibitor,
JQ1. JQ1 functions as a speciﬁc inhibitor of BET bromodomain
binding of acetylated lysines in chromatin and has demonstrated
single agent efﬁcacy in diverse cancer models (Delmore et al,
2011; Filippakopoulos et al, 2010; Mertz et al, 2011; Ott et al, 2012;
Zuber et al, 2011) but has not previously been tested in
combination treatment with a therapeutic monoclonal antibody.
CYCLON suppression speciﬁcally sensitized lymphoma cells
to Rituximab‐dependent CDC and direct killing, but not to ADCC
or indeed other apoptotic stimuli. This suggests the regulation by
CYCLON of cell intrinsic mechanisms downstream of direct
CD20 engagement and/or Rituximab Fc fragment activity which
is required for complement activation but is dispensable for
CD20 signalling per se (Vega et al, 2009). BET bromodomain
inhibition appears to break Rituximab resistance in lymphoma B
cells showing coincident MYC and CYCLON overexpression.
This could operate by reducing CYCLON levels to critically low
thresholds, whichmight affect key, high‐afﬁnity, CYCLON target
genes directly or indirectly impacting on Rituximab response. In
keeping with this, CYCLON and JQ1 regulate a number of genes
that encode factors of relevance to lymphoma B‐cell survival,
including the inhibitor of NFKB signalling, NFKBIA as well as
JNK1, known to be involved in complement‐mediated cytotox-
icity (Gancz et al, 2009; Jeon et al, 2009). Noteworthy, is that
constitutive NFKB signalling has been linked to experimental
resistance to Rituximab in lymphoma cell lines (Jazirehi
et al, 2007). One could also bear in mind that maintenance
therapy with Rituximab alone is being explored in DLBCL
(Michallet et al, 2012). Association of Rituximab with BET
bromodomain inhibitors in this setting might be an attractive
therapeutic option.
We also identiﬁed Rituximab‐resistant, lymphoma B cells that
overexpress CYCLON, without concomitant MYC deregulation,
thus pointing to the existence of other as yet un‐identiﬁed routes
to CYCLON overexpression in lymphoma. BET bromodomain
inhibition does not relieve Rituximab resistance in these cells
suggesting that coincident MYC and CYCLON overexpression
could be used as a biomarker to identify patients most likely to
respond to BET bromodomain inhibitor and Rituximab combi-
nation therapy.
CYCLON has been shown to play a key role in maintaining
normal T‐cell homeostasis following cellular activation (Saint
Fleur et al, 2009). This occurs through up‐regulation, by
CYCLON, of CD95 expression in activated but not resting T
cells. The CD95 pathway is also involved in maintaining B‐cell
homeostasis downstream of B‐cell receptor signalling and in the
germinal centre reaction (Hao et al, 2008). It is thus possible that
CYCLON also regulates CD95 expression in discrete stages of
normal B‐cell development. Indeed, we uncovered CYCLON
expression, albeit at low levels, in normal GC B‐cell subsets.
CYCLON might also contribute to the control of mature B‐cell
development downstream of MYC. In support of this notion,
normal germinal center B‐cell subsets, deﬁned by either high or
low MYC levels have recently been identiﬁed (Calado et al, 2012;
Dominguez‐Sola et al, 2012). Signiﬁcantly, at least in mice,
normal ‘highMYC’GC B cells are characterized by a speciﬁc gene
expression signature, that includes numerous B‐cell activation
response genes (including CD40 signalling components), and
up‐regulation of Cyclon/Ccdc86 (Dominguez‐Sola et al, 2012).
Normal, ‘high MYC’, GC B cells are essential for both the early
and late phases of the germinal center reaction and appear to be
poised for re‐entry to the dark zone for further rounds of afﬁnity
maturation (Calado et al, 2012; Dominguez‐Sola et al, 2012). We
have shown that CYCLON deregulation is predominant, albeit
not exclusive to, ‘high MYC’ DLBCL tumours, of both the GCB
and ABC subtypes. At least for the former, it is tempting to
speculate that CYCLON deregulation occurs as ‘collateral
damage’ downstream of MYC deregulation, by chromosomal
translocation or other event (MYC gene rearrangement is
common DLBCL of the GCB subtype). This would uncouple
not only MYC, as previously postulated (Dominguez‐Sola
et al, 2012), but also CYCLON‐dependent gene regulatory
circuits, from normal afﬁnity maturation, thus facilitating
malignant reprogramming of the affected B cells, ultimately
leading to disturbed GC dynamics and lymphomagenesis. In
this respect, it is noteworthy that CYCLON regulates gene
expression signatures of direct relevance to the pathogenesis of
germinal center‐derived lymphoma. Of speciﬁc interest is
CYCLON‐mediated suppression of NFKB2 expression. NFKB2
is also a MYC repression target and Nfkb2 loss has been shown
to accelerate lymphoma development in Em‐Myc transgenic
mice (Keller et al, 2010). This works suggests that BET
bromodomain inhibition could override these oncogenic signal-
ling events.
In conclusion, we have devised a proteomics‐driven strategy
to leverage illegitimate gene activation events for the discovery
of new treatment strategies in high risk B‐cell lymphoma. A
remarkable result was the identiﬁcation of a MYC‐controlled
disease progression and Rituximab resistance regulatory circuit
that is autonomously controlled by the nuclear factor CYCLON.
This CYCLON‐MYC regulatory axis can be blocked by
BET bromodomain inhibitors thus opening avenues for new
anti‐lymphoma treatment strategies based on combining anti‐
CD20 monoclonal antibodies and next generation epigenetic
therapy.
MATERIALS AND METHODS
Cell culture, reagents and antibodies
B593 DLBCL cell line was derived in house (Callanan et al, 2000).
SUDHL4, HT (DLBCL lines) and Raji (BL line) were purchased from
DMSZ. OCI‐Ly3 and OCI‐Ly10 were kindly provided by Professor Georg
Lenz. Cells were cultured in RPMI medium supplemented with 2 mM
GlutaMAX®, 1 mM sodium pyruvate, 25 mM HEPES, non‐essential
amino acids, 100 mg/mL Penicillin/Streptomycin solution and 10%
foetal calf serum (Invitrogen), except for OCI‐LY3 and OCI‐Ly10 which
were cultured in IMDM 20% human serum (Cambrex) supplemented
with 2 mM GlutaMAX®, 1 mM sodium pyruvate, 25 mM HEPES, non‐
essential amino acids, 100 mg/mL Penicillin/Streptomycin solution
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(added with 50 mM b‐mercaptoethanol for OCI‐Ly3 cell line). Unless
otherwise speciﬁed, all chemicals were purchased from Sigma–Aldrich.
Anti‐CYCLON antibody was obtained 28 days after rabbit immuniza-
tion with both C and N‐terminus CYCLON peptides and antibody
afﬁnity‐puriﬁcation against the C‐terminus peptides from immune
serum (Speed Rabbit program, Eurogentec) or purchased from Bethyl
Laboratories. Anti‐MYC (clone 9E10) and anti‐H3 were obtained from
Santa Cruz and Millipore, respectively. Rituximab (Mabthera®, Roche)
and Herceptin (Trastuzumab®, Roche) were obtained at Grenoble
University Hospital pharmacy.
JQ1 synthesis
()‐JQ1 was synthesized using the procedure published by Filippa-
kopoulos et al (Filippakopoulos et al, 2010). Highly puriﬁed ()‐JQ1
was obtained by column chromatography (gradient n‐hexane/ethyl
acetate 8:2 to 100% ethyl acetate) followed by precipitation from ethyl
ether by n‐hexane. The ﬁnal compound was characterized by 1H NMR
(Supporting Information Fig S6A), MS (Supporting Information Fig S6B)
and HPLC (using an analytical OD‐H chiral column) (Supporting
Information Fig S6C). Enantiomeric composition of the crystalline
product was veriﬁed by chiral HPLC to be 55% active enantiomer (þ)‐
JQ1 (OD‐H analytical column; n‐hexane/2‐propanol 85:15; (þ)‐JQ1 r.t.:
10 min, ()‐JQ1 r.t.: 12 min).
Protein extraction and mass spectrometry analysis
Whole cell lysates were obtained by sonication of cell pellets in
Laemmli buffer. Nuclear acid soluble fractions were obtained by direct
sonication of cell nuclei in 0.2 N sulphuric acid (see Supporting
Information Fig S1A) as described previously (Govin et al, 2006) and
separated by SDS‐PAGE (20 mg protein per lane) following Coomassie
staining. MS analyses were performed on three biological replicates.
Trypsin in‐gel digestion and LC‐MS/MS analysis were performed as
described previously (Dos Santos et al, 2010). MS/MS data were
acquired and processed automatically using Xcalibur™ 1.4 software
(Thermo Fisher Scientiﬁc).
Protein identiﬁcation by mass spectroscopy
MS data were analysed using the Mascot 2.1 program (Matrix Science)
with compilation of SwissProt and Trembl databases (release 50.1/33.1,
3,192,898 entries in total including 17,483 human, June 2006) using
Homo sapiens as selected species.The variablemodiﬁcations allowed are
listed at the bottom of Table S1. Mass accuracy was set to 10 ppm for
precursor ion and 0.8 Da for fragments. Mascot data were then
transferred to IRMa validation software (Dupierris et al, 2009), which
allowed data ﬁltering and suppression of protein redundancy on the
basis of proteins being identiﬁed by a same set or a subset of peptides
(Target Decoy approach (Choi et al, 2008): FDR ¼ 1.6%). Manually
validated hits from each of the three biological replicates were
transferred to a relational database. Protein abundance was estimated
using the spectral counting method (Gilchrist et al, 2006). Molecular
weight, subcellular localization and associated functions were retrieved
for each protein from Uniprot (http://www.expasy.uniprot.org/).
Gene expression analysis by RT‐qPCR
Total RNA was extracted from cell lines, tissues or sorted B cells by
TRIzol reagent (Invitrogen) and quantiﬁed by NanoDrop (Thermo Fisher
Scientiﬁc) before being reverse transcribed using the SuperScript® III
First‐Strand Synthesis SuperMix for RT‐qPCR (Invitrogen), according to
manufacturer’s instructions. qPCR was performed using SYBR® Green
PCR master mix (Applied Biosystems) and primers shown in Table S5,
according to the manufacturer’s instructions. The ABL gene was used as
a control for normalization of gene expression data. qPCR was
performed on an MX3000P (Stratagene) machine.
Microarray gene expression analysis
Affymetrix microarrays were processed in the Microarray Core Facility
of the Institute of Research on Biotherapy, CHRU‐INSERM‐UM1
Montpellier (http://irb.chu‐montpellier.fr/). RNA was ampliﬁed using
the kit GeneChip IVT express and hybridized to HG U133 Plus 2.0
microarrays according to manufacturer’s instructions (Affymetrix).
Fluorescence intensities were quantiﬁed using the GCOS 1.2 software.
Gene expression data were normalized with RMA algorithm and
analyzed using GeneSpring software package (Agilent). Data have
been deposited in the NCBI Gene Expression Omnibus (GEO, series
accession GSE46873).
To identify the predominant normal tissue expression patterns of
the 236 proteins identiﬁed in the index DLBCL cell line NAS proteome
(B593 cells), gcRMA‐normalized Affymetrix gene expression data
from 79 normal human tissues were retrieved from the BioGPS portal
(http://biogps.org/) (Su et al, 2004). A given factor was scored as
showing ‘off‐context’ expression in lymphoma, if its normal tissue
expression pattern was predominantly non‐lymphoid; i.e. if the factor
in question showed expression of 10‐fold above the median in a given
non‐lymphoid cell or tissue type and below median expression in
normal lymphoid tissues or cells. The median was calculated across
all 79 normal cell or tissue types (Su et al, 2004).
Additional published normal lymphoid and lymphoma transcrip-
tomic data were as follows; GSE2350 (Basso et al, 2005), GSE10846
(Lenz et al, 2008), GSE4475 (Hummel et al, 2006) and GSE29449
(Mertz et al, 2011). Processed data were retrieved through the GEO
portal (http://www.ncbi.nlm.nih.gov/geo/). Transcriptomic data from
the MYC‐inducible B‐cell line, P493 (Schlosser et al, 2005) were kindly
provided by Professor Dirk Eick. Following normalization, clustering
and seriation, data were visualized as heat‐maps using the
PermutMatrix software (http://www.lirmm.fr/caraux/Permut Matrix/)
(Caraux & Pinloche, 2005). The following data treatment options
were used: Euclidian distance of dissimilarity, McQuitty’s method
of hierarchical clustering and multiple fragment heuristic seriation
rule.
GSEA analysis
GSEA is a computational method that determines whether an a
priori deﬁned set of genes shows statistically signiﬁcant, concordant
differences between two biological states (Subramanian et al, 2005).
Analysis was performed using GSEA v2.07 software against the c2 gene
sets from the Broad Institute Molecular Signature Database (http://
www.broadinstitute.org/gsea/msigdb/). A detailed description of
GSEA methodology and interpretation is provided online (http://
www.broadinstitute.org/gsea/doc/GSEAUserGui‐deFrame.html). In brief,
the normalized enrichment score (NES) provides ‘the degree to which a
gene set is overrepresented at the top or bottom of a ranked list of
genes’. The false discovery rate q‐value (FPREFIXDR > q‐val) is ‘the
estimated probability that a gene set with a given NES represents a
false positive ﬁnding’.
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Immunoblot
Protein lysates were resolved by SDS‐PAGE and transferred onto
nitrocellulose membranes for blotting with anti‐CYCLON, anti‐MYC
or anti‐H3 antibodies. After treatment with blocking solution
(1 PBS, 8% skimmed milk, 0.1% Tween 20), membranes were
incubated with primary antibody (CYCLON, 0.2 mg/mL, MYC,
0.5 mg/mL, H3 0.1 mg/mL in PBS 3% skimmed milk 0.1% Tween
20), washed and incubated with anti‐rabbit or mouse IgG‐HRP
(Thermo Fisher Scientiﬁc) before incubation in ECL SuperSignal West
Pico Chemiluminescent Substrate (Thermo Fisher Scientiﬁc). Images
were captured using a ChemiDoc XRSþ imager system (Biorad) or
autoradiography ﬁlms.
CD20 surface expression analysis
Membrane CD20 expression was determined by direct ﬂuorescence.
Brieﬂy, 5  105 cells/mL were incubated for 20 min at 4 °C with FITC‐
conjugated, anti‐CD20 monoclonal antibody (clone 2H7, Ozyme).
Immunostained cells were analyzed by ﬂow cytometry (LSRII, BD). Non‐
speciﬁc staining was determined using an FITC‐conjugated control IgG
(IgG2bk, clone MG2b‐57, Ozyme). Percentages of positive cells and
mean ﬂuorescence intensities (MFI) were recorded and analyzed with
FCS express software.
Gene silencing
Non‐targeting or CYCLON targeting short hairpin (sh) RNA sequences
were designed using the DSIR algorithm (http://biodev.cea.fr/DSIR/DSIR.
html) (Vert et al, 2006). Sequences provided in Table S5, were cloned
into the pLKO‐1 lentiviral vector (Addgene) and packaged, as described
(Levy et al, 2010). pLKO‐1 expressingMYC targeting shRNA sequences A
and B were a gift from Dr Alessio Zippo (Zippo et al, 2007). Cells were
transduced with lentiviral particles at an MOI (multiplicity of infection)
of 10. Stable cell lines were established under puromycin selection
(1 mg/mL). Knockdown efﬁciency was assessed by western blotting and
RT‐qPCR.
Evaluation of Rituximab sensitivity
A total of 5  105 cells were treated with Rituximab (Roche) or control
IgG (Herceptin, Roche): 24 h with a dose of 10 mg/mL for direct killing
assays and 1 h with a dose of 1 mg/mL in presence of 20% human
serum as a source of complement, for CDC assays. Cell viability
was evaluated by Annexin V/propidium iodide (PI) double staining
(Beckman Coulter) or PI staining, followed by ﬂow cytometry analysis
(LSRII, BD). Speciﬁc cell death was calculated as (% of cell death with
Rituximab  % cell death with Herceptin)/(1  % cell death with
Herceptin).
Xenotransplantation assay
All animal experiments were conducted in agreement with the
Principles of Laboratory Animal Care (National Institutes of Health
publication no. 86‐23, revised 1985) and approved by the regional
ethics committee. Raji cells (5.106) were injected subcutaneously into
the ﬂanks of 6–8 week‐old SCID mice (Charles River), as described
(Chao et al, 2010). For follow‐up of tumour engraftment and growth,
12 mice each were injected into the right and left ﬂanks, respectively,
with either shCtrl or shCYCLON‐transduced Raji cells expressing
luciferase. For Rituximab treatment and survival analysis, 24mice were
injected into the right ﬂank, with either shCtrl or shCYCLON‐
transduced Raji cells expressing luciferase. When tumours were
palpable (0.5 mm3), mice were given daily intraperitoneal injections
of 200 mg Rituximab or control IgG (Non Swiss Albino Mouse IgG,
Innovative research). Tumour volume was measured every 2 days and
calculated using the formula l2  L  0.52 (n ¼ 6 for each group).
The paper explained
PROBLEM:
B-cell non-Hodgkin lymphoma (B-NHL) comprises a complex
spectrum of lymphoid cancers that manifest heterogeneous
clinical outcomes to standardized therapies tailored to well-
defined subtypes. A significant advance in treatment of
aggressive B-NHL has been achieved with anti-CD20monoclonal
antibodies (Rituximab) both in combination with chemotherapy
or alone as a maintenance treatment. However, a proportion of
patients fail to respond to, or more commonly relapse, after
receiving Rituximab-containing therapy. The cellular and
molecular mechanisms underlying these events are not well
characterized and treatment strategies to override treatment
resistance events are lacking.
RESULTS:
To discover new factors involved in tumour progression and
treatment resistance in aggressive lymphoma, we developed a
transcriptome-driven proteomics approach focused on the
identification of illegitimately activated factors, termed here ‘off-
context’, that are involved in oncogenic signalling and treatment
resistance in high risk B-cell lymphoma. Using this strategy, we
identified the nuclear factor CYCLON, which has not been
previously connected to cancer, as a novel transcriptional
regulator of the mature B-cell development program that
autonomously drives tumour growth and resistance to mono-
clonal antibody therapy in B-cell NHL. Strikingly, CYCLON activity
can be targeted through BET bromodomain inhibition down-
stream of MYC.
IMPACT:
This work provides new biological insights into disease
progression and treatment resistance in aggressive lymphoid
cancers and provides proof of principle that systematic searches
for ‘off-context’ gene expression events is a powerful approach
for discovering new oncogenic and treatment resistance
mechanisms in cancer.
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Bioluminescence imaging was performed weekly, under inhaled
anaesthesia (3% isoﬂurane), administered through a nose cone. Mice
then received an intraperitoneal injection of D‐luciferin potassium salt
dissolved in sterile phosphate‐buffered serum (150 mg/kg) 10 min
before imaging (ORCAII‐BT‐512G, Hamamatsu Photonics), as described
previously (Jin et al, 2006). Semi‐quantitative data were obtained from
the bioluminescence images by drawing regions of interest on the area
to be quantiﬁed. Results were expressed as the number of relative light
units (RLU) per pixel per second.
Cell death assays
Cell death assays were undertaken using JQ1 (dose and time as
indicated) and for 24 h with 20 nM etoposide or 1 mg/mL 7C11
antibody to engage FAS receptor death signalling, as described
(Lajmanovich et al, 2009). Cell viability was evaluated by AnnexinV/IP
(Beckman Coulter) or IP staining and ﬂow cytometry analysis (LSIIR,
BD). Speciﬁc cell death was calculated as (% of drug‐induced cell
death  % control cell death)/(1  % control cell death) as described
(Lajmanovich et al, 2009).
Statistics
Excel® 2010 (Microsoft) and J.M.P.® 10.0.0 (SAS Institute) software
were used for graphical representations and to perform statistical
analysis across all experiments and for survival analysis. For the latter,
CYCLON values at diagnosis were deﬁned as high (above 3rd quartile)
or low (below 1st quartile) and Kaplan–Meier survival curves and the
log‐rank test used to estimate overall survival. Survival analysis in
lymphoma xenograft experiments was performed by the Kaplan–Meier
method and the p‐value calculated by log‐rank test.
The Wilcoxon non‐parametric method or the two‐sided Student
t test were used for statistical analysis in gene expression and cell
death analyses and in in vivo tumour growth and Rituximab response
assays to assess statistical signiﬁcance. Histograms represent the
average for each group and errors bars represent standard error of
the mean.
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